AOD-9604
Growth-hormone fragment researched for fat-axis and lipolysis.
AOD-9604
Background
AOD-9604 is a synthetic peptide corresponding to the C-terminal fragment (residues 176-191) of human growth hormone, engineered to retain the proposed lipolytic and anti-lipogenic activity of the parent hormone without its effects on growth or insulin sensitivity. Research has examined its action on adipose-tissue fat metabolism.
Originally advanced as a candidate anti-obesity agent, it showed lipolytic activity in preclinical models, though clinical efficacy outcomes were inconclusive. It has no approved therapeutic indication.
Selected literature
- Heffernan MA, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice. Endocrinology. 2001;142(12):5182-5189.
- Ng FM, et al. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Hormone Research. 2000;53(6):274-278.
- Stier H, et al. Safety and tolerability of the hexadecapeptide AOD9604 in humans. Journal of Endocrinology and Metabolism. 2013.
References are provided for scientific context only. Citation does not imply endorsement of any use, nor a claim of safety or efficacy. Findings frequently derive from in-vitro or animal models.
Trademarks & attribution
AOD-9604 was originally developed by Metabolic Pharmaceuticals Ltd. It has no approved trademarked drug product. Catalyst Research Labs is not affiliated with that organization. Supplied as reference material only.
